Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will present at the Jefferies Global Healthcare Conference scheduled for November 17-20, 2025, in London. The presentation provides an important platform for the company to showcase its progress in developing proprietary drug discovery platforms and delivery systems aimed at transforming mental healthcare.
The company's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies. Cybin is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational 5-HT-receptor focused compounds.
Cybin's participation in the prestigious Jefferies conference underscores the growing investor interest in novel mental health treatments and the neuropsychiatry sector. The company's focus on developing next-generation treatment options addresses the large unmet need for effective mental healthcare solutions. With promising class-leading data, Cybin aims to introduce novel drugs that provide effective and durable results for patients suffering from mental health conditions.
The full press release detailing Cybin's conference participation is available at https://ibn.fm/bb3sl. Investors seeking additional information about the company can access the latest news and updates in Cybin's newsroom at https://ibn.fm/CYBN. The conference presentation represents a significant opportunity for Cybin to demonstrate its progress in advancing innovative treatments for mental health disorders that affect millions worldwide.